PALATIN TECHNOLOGIES INC

PTNNASDAQ

🏆 #4064 by market capEarnings Sep 21 · PostUS Equity

$7.41▲ $0.05 (+0.68%)

🌅 Pre-market$7.41▲ 0.00%Regular close · extended-hours price shown

1h—

24h▲ 0.7%

7d▼ 3.8%

14d▼ 2.6%

30d▼ 24.5%

1y—

🏦Market Cap

$13M

Small Cap

📈Revenue Growth (YoY)

+3581.2%

High Growth

📊Gross Margin

97.8%

High

💵FCF Margin

29.6%

Strong

⚖️P/S Ratio

1.1x

Cheap

Otter Score

Fair

Trading Snapshot

Day Range: $7.36 – $7.47
52-Week Range: $5.00 – $31.00
Volume: $3.63B
Avg Volume: $4.54B
Shares Outstanding: 1.8M
Next Earnings: Sep 24, 2026

Fundamentals Snapshot

Annual Revenue: $12M
Last Q Revenue: $4M
P/E Ratio: —
P/S Ratio: 1.1x
EPS (TTM): $-1.69
Dividend Yield: —

Why Investors Own PTN

✓High-growth profile — revenue up +40.7% YoY with expanding US Equity exposure.
✓Healthy economics — 71% gross margin and 23% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$12M▲ +41.2% YoY

Gross Margin (TTM)

70.5%▲ +3.7% YoY

Operating Income (TTM)

$1M▲ +41.2% YoY

Free Cash Flow (TTM)

$3M▲ +41.2% YoY

About PALATIN TECHNOLOGIES INC

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.

🦦